Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns

Neurotherapeutics

Volumn 13, Issue 4, 2016, Pages 671-684

  Bustamante, Alejandro ^a   Simats, Alba ^a   Vilar Bergua, Andrea ^a   García Berrocoso, Teresa ^a   Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Alarmins; Biomarkers; C reactive protein; Cytokines; Inflammation; Outcome; Stroke

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEROXIREDOXIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; CYTOKINE;

BLOOD BRAIN BARRIER; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ANIMAL; COMPLICATION; IMMUNOLOGY; METABOLISM;

ANIMALS; BIOMARKERS; C-REACTIVE PROTEIN; CYTOKINES; HUMANS; INFLAMMATION; STROKE;

EID: 84982281173     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-016-0470-2     Document Type: Review

References (155)

1. Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 2016; 133: e38-e360.
2. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modeling. Lancet Neurol 2009; 8: 345-354.
3. Murray JL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223.
4. Bustamante A, Garcia-Berrocoso T, Rodriguez N, et al. Ischemic stroke outcome: a review of the influence of post-stroke complications within the different scenarios of stroke care. Eur J Intern Med 2016; 29: 9-21.
5. Katan M, Elkind MSV. Inflammatory and neuroendocrine biomarkers of prognosis after ischemic stroke. Expert Rev Neurother 2011; 11: 225-239.
6. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009; 40: 380-389.
7. Bustamante A, Garcia-Berrocoso T, Llombart V, Simats A, Giralt D, Montaner J. Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: overcoming the major hurdles. Expert Rev Neurother 2014; 14: 1391-1403.
8. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res 2007; 54: 34-66.
9. Liesz A, Dalpke A, Mracsko E, et al. DAMP signaling is a key pathway inducing immune modulation after brain injury. J Neurosci 2015; 35: 583-598
10. Fumagalli S, Perego C, Pischiutta F, Zanier ER, De Simoni MG. The ischemic environment drives microglia and macrophage function. Front Neurol 2015; 6: 1-19.
11. Li L, Lundkvist A, Andersson D, et al. Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab 2008; 28; 468-481.
12. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009; 11: 1-11.
13. Liesz A, Hu X, Kleinschnitz C, Offner H. Functional role of regulatory lymphocytes in stroke: facts and controversies. Stroke 2015; 46: 1422-1430.
14. Esmaeili A, Dadkhahfar S, Fadakar K, Rezaei N. Post-stroke immunodeficiency: effects of sensitization and tolerization to brain antigens. Int Rev Immunol 2012; 31: 396-409.
15. Colivicchi F, Bassi A, Santini M, Caltagirone C. Cardiac autonomic derangement and arrhythmias in right-sided stroke with insular involvement. Stroke 2004; 35: 2094-2098.
16. Ozbalkan Z, Efe C, Cesur M, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis 2010; 212: 377-382.
17. Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke. Stroke 2000; 31: 1521-1525.
18. Joshipura KJ. The relationship between oral conditions and ischemic stroke and peripheral vascular disease. J Am Dent Assoc 2002; 133: 23S-30S.
19. Das S, Ghosh KC, Pulai S, Pulai D, Bhar D, Gangopadhyay PK. Systemic infection and inflammation as trigger factors of ischemic stroke. Ann Neurosci 2011; 18: 17-20.
20. Zhao B, Schwartz JP. Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives. J Neurosci Res 1998; 52: 7-16.
21. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184: 53-68.
22. Hossmann KA. Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol. 2006; 26: 1057-1083.
23. Lai AY, Todd KG. Microglia in cerebral ischemia: molecular actions and interactions. Can J Physiol Pharmacol 2006; 84: 49-59.
24. Vitkovic L, Maeda S, Sternberg E. Anti-inflammatory cytokines: expression and action in the brain. Neuroimmunomodulation 2001; 9: 295-312.
25. Sriram K, O’Callaghan JP. Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol 2007; 2: 140-153.
26. Simats A, García-Berrocoso T, Montaner J. Neuroinflammatory biomarkers: from stroke diagnosis and prognosis to therapy. Biochim Biophys Acta 2016; 1862: 411-424.
27. Simi A, Tsakiri N, Wang P, Rothwell NJ. Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans 2007; 35: 1122-1126.
28. del Zoppo GJ. Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience 2009; 158: 972-982.
29. Rothwell N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun 2003; 17: 152-157.
30. Protopsaltis J, Kokkoris S, Korantzopoulos P, et al. Prediction of long-term functional outcome in patients with acute ischemic non-embolic stroke. Atherosclerosis 2009; 203: 228-235.
31. Tanzi P, Cain K, Kalil A, et al. Post-stroke infection: a role for IL-1ra? Neurocrit Care 2011; 14: 244-252.
32. Becker KJ, Dankwa D, Lee R, et al. Stroke, IL-1ra, IL1RN, infection and outcome. Neurocrit Care 2014; 21: 140-146.
33. Emsley HC, Smith CJ, Georgiou RF, et al. A randomised Phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol Neurosurg Psych 2005; 76: 1366-1372.
34. Pan W, Kastin AJ. Tumor necrosis factor and stroke: role of the blood brain barrier. Prog Neurobiol 2007; 83: 363-374.
35. Gregersen R, Lambertsen K, Finsen B. Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 2000; 20: 53-65.
36. Sharp FR, Lu A, Tang Y, Millhorn DE. Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 2000; 20: 1011-1032.
37. Zou JY, Crews FT. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 2005; 1034: 11-24.
38. Christov A, Ottman JT, Grammas P. Vascular inflammatory, oxidative and protease-based processes: implications for neuronal cell death in Alzheimer’s disease. Neurol Res 2004; 26: 540-546.
39. Castellanos M, Castillo J, Garcia MM et al. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002; 33: 982-987.
40. Rodríguez JA, Sobrino T, Orbe J, et al. proMetalloproteinase-10 is associated with brain damage and clinical outcome in acute ischemic stroke. J Thromb Haemost 2013; 11: 1464-1473.
41. Whiteley W, Wardlaw J, Dennis M, et al. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 2012; 43: 86-91.
42. Rodríguez-Yáñez M, Castellanos M, Sobrino T, et al. Interleukin-10 facilitates the selection of patients for systemic thrombolysis. BMC Neurol 2013; 13: 62.
43. Chamorro A, Amaro S, Vargas M, et al. Catecholamines, infection, and death in acute ischemic stroke. J Neurol Sci 2007; 252: 29-35.
44. Salat D, Penalba A, García-Berrocoso T, et al. Immunological biomarkers improve the accuracy of clinical risk models of infection in the acute phase of ischemic stroke. Cerebrovasc Dis 2013; 35: 220-227.
45. Boehme AK, McClure LA, Zhang Y, et al. Inflammatory markers and outcomes after lacunar stroke: levels of inflammatory markers in treatment of stroke study. Stroke 2016; 47: 659-667.
46. Legos JJ, Whitmore RG, Erhardt JA, Parsons AA, Tuma RF, Barone FC. Quantitative changes in interleukin proteins following focal stroke in the rat. Neurosci Lett 2000; 282: 189-192.
47. Clark WM, Rinker LG, Lessov NS, et al. Lack of interleukin-6 expression is not protective against focal central nervous system ischemia. Stroke. 2000; 31: 1715-1720.
48. Castillo J, Alvarez-Sabín J, Martínez-Vila E, et al; MITICO Study Investigators. Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study. J Neurol 2009; 256: 217-224.
49. Vila N, Castillo J, Dávalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325-2329.
50. Smith CJ, Emsley H, Gavin CM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004; 4: 2.
51. Waje-Andreassen U, Krakenes J, Ulvestad E, et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005; 111; 360-365.
52. Orion D, Schwammenthal Y, Reshef T, et al. Interleukin-6 and soluble intercellular adhesion molecule-1 in acute brain ischaemia. Eur J Neurol 2008; 15: 323-328.
53. Wartenberg KE, Stoll A, Funk A, Meyer A, Schmidt JM, Berrouschot J. Infection after acute ischemic stroke: risk factors, biomarkers, and outcome. Stroke Res Treat 2011; 2011: 830614.
54. Zhang X, Wang F, Zhang Y, Ge Z. Risk factors for developing pneumonia in patients with diabetes mellitus following acute ischaemic stroke. J Int Med Res 2012; 40: 1860-1865.
55. Bustamante A, Sobrino T, Giralt D, et al. Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and meta-analysis. J Neuroimmunol 2014; 274: 215-224.
56. Pantoni L, Sarti C, Inzitari D. Cytokines and cell adhesion molecules in cerebral ischemia: experimental bases and therapeutic perspectives. Arterioscler Thromb Vasc Biol 1998; 18: 503-513.
57. Ma M, Ma Y, Yi X, et al. Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neurosci 2008; 9: 117.
58. Rustenhoven J, Aalderink M, Scotter EL, et al. TGF-beta1 regulates human brain pericyte inflammatory processes involved in neurovasculature function. J Neuroinflammation 2016; 13: 37.
59. Urra X, Cervera A, Obach V, Climent N, Planas AM, Chamorro A. Monocytes are major players in the prognosis and risk of infection after acute stroke. Stroke 2009; 40: 1262-1268.
60. Worthmann H, Tryc AB, Dirks M, et al. Lipopolysaccharide binding protein, interleukin-10, interleukin-6 and C-reactive protein blood levels in acute ischemic stroke patients with post-stroke infection. J Neuroinflammation 2015; 12: 13.
61. Kuta AE, Baum LL. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med 1996; 164: 321-326.
62. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-1051.
63. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
64. Emsley HC, Smith CJ, Gavin CM, et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003; 139: 93-101.
65. Di Napoli M, Schwaninger M, Cappelli R, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005; 36: 1316-1329.
66. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005; 165: 2479-2484.
67. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006; 166: 2073-2080.
68. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32: 917-924.
69. Masotti L, Ceccarelli E, Forconi S, Cappelli R. Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. J Intern Med 2005; 258: 145-152.
70. Montaner J, Fernandez-Cadenas I, Molina CA et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006; 37: 1205-1210.
71. Molnar T, Papp V, Banati M, et al. Relationship between C-reactive protein and early activation of leukocytes indicated by leukocyte antisedimentation rate (LAR) in patients with acute cerebrovascular events. Clin Hemorheol Microcirc 2010; 44: 183-192.
72. Modrego PJ, Boned B, Berlanga JJ, Serrano M. Plasmatic B-type natriuretic peptide and C-reactive protein in hyperacute stroke as markers of CT-evidence of brain edema. Int J Med Sci 2008; 5: 18-23.
73. García-Berrocoso T, Giralt D, Bustamante A, et al. B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis. Neurology 2013; 81: 1976-1985.
74. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
75. Gelderbloma M, Sobeyb CG, Kleinschnitzc C, Magnusa T. Danger signals in stroke. Ageing Res Rev; 2015; 24: 77-82.
76. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342.
77. Kim JB. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006; 26: 6413-6421.
78. Qiu J, Nishimura M, Wang Y, et al. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008; 28: 927-938.
79. Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22: 5551-5560.
80. Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results inIL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005; 106: 609-616.
81. Tang SC, Arumugam TV, Xu X, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 2007; 104: 13798-13803.
82. Huang JM, Hu J, Chen N, Hu ML. Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke. J Crit Care 2013; 28: 792-797.
83. Sapojnikova N, Kartvelishvili T, Asatiani T, et al. Correlation between MMP-9 and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome. Biochim Biophys Acta 2014; 1842: 1379-1384.
84. Schulze J, Zierath D, Tanzi P, et al. Severe stroke induces long-lasting alterations of high-mobility group box 1. Stroke 2013; 44: 246-248.
85. Sokół B, Woźniak A, Jankowski R, et al. HMGB1 level in cerebrospinal fluid as a marker of treatment outcome in patients with acute hydrocephalus following aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 2015; 24: 1897-1904.
86. Bukau B, Horwich AL. The Hsp70 and Hsp60 chaperone machines. Cell 1998; 92: 351-366.
87. Kim JY, Yenari MA. The immune modulating properties of the heat shock proteins after brain injury. Anat Cell Biol 2013; 46: 1-7.
88. Sharp FR, Zhan X, Liu DZ. Heat shock proteins in the brain: role of Hsp70, Hsp 27, and HO-1 (Hsp32) and their therapeutic potential. Transl Stroke Res 2013: 4; 685-692.
89. Gómez-Choco M, Doucerain C, Urra X, Planas AM, Chamorro A. Presence of heat shock protein 70 in secondary lymphoid tissue correlates with stroke prognosis. J Neuroimmunol 2014; 270: 67-74.
90. Azarpazhooh MR, Mobarra N, Parizadeh SM, et al. Serum high-sensitivity C-reactive protein and heat-shock protein 27 antibody titers in patients with stroke and 6-month prognosis. Angiology 2010; 61: 607-612.
91. Campos-Martorell M, Salvador N, Monge M, et al. Brain proteomics identifies potential simvastatin targets in acute phase of stroke in a rat embolic model. J Neurochem 2014; 130: 301-312.
92. Montaner J, Chacón P, Krupinski J, et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008; 15: 82-90.
93. Hanschmann AM, Godoy JR, Berndt C, Hudemann C, Lillig CH. Thioredoxins, glutaredoxins, and peroxiredoxins—molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. Antioxid Redox Signaling 2013; 19: 1539-1605.
94. Shichita T, Hasegawa E, Kimura A, et al. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med 2012; 18: 911-917.
95. Dayon L, Turck N, García-Berrocoso T, Walter N, Burkhard PR, Vilalta A, et al. Brain extracellular fluid protein changes in acute stroke patients. Proteome Res 2011; 10: 1043-1051.
96. Kunze A, Zierath D, Tanzi P, Cain C, Becker K. Peroxiredoxin 5 (PRX5) is correlated inversely to systemic markers of inflammation in acute stroke. Stroke 2014; 45: 608-610.
97. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
98. Pruenster M, Kurz AR, Chung KJ, et al. Extracellular MRP8/14 is a regulator of β2 integrin-dependent neutrophil slow rolling and adhesion. Nat Commun 2015; 6: 6915.
99. Qiang X, Yang WL, Wu R, et al. Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis. Nat Med 2013; 19: 1489-1495.
100. Kwan J, Horsfield G, Bryant T, et al. IL-6 is a predictive biomarker for stroke associated infection and future mortality in the elderly after an ischemic stroke. Exp Gerontol 2013; 48: 960-965.
101. Castellanos M, Sobrino T, Pedraza S, et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 2008; 71: 1862-1868.
102. Castillo J, Moro MA, Blanco M, et al. The release of tumor necrosis factor-alpha is associated with ischemic tolerance in human stroke. Ann Neurol 2003; 54: 811-819.
103. Blanco M, Castellanos M, Rodríguez-Yáñez M, et al. High blood pressure and inflammation are associated with poor prognosis in lacunar infarctions. Cerebrovasc Dis 2006; 22: 123-129.
104. Rodríguez-Yáñez M, Castellanos M, Blanco M, et al. New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke. Neurology 2006: 67; 1973-1978.
105. Oto J, Suzue A, Inui D, et al. Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients. J Anesth 2008; 22: 207-212.
106. Basic-Kes V, Simundic AM, Nikolac N, Topic E, Demarin V. Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem 2008; 41: 1330-1334.
107. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis 2009: 27; 247-253.
108. Whiteley W, Jackson C, Lewis S, et al. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 2009; 6: e1000145.
109. Worthmann H, Tryc AB, Goldbecker A, et al. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis 2010; 30: 85-92.
110. Brea D, Sobrino T, Rodríguez-Yáñez M, et al. Toll-like receptors 7 and 8 expression is associated with poor outcome and greater inflammatory response in acute ischemic stroke. Clin Immunol 2011; 139: 193-198.
111. Rodríguez-González R, Sobrino T, Rodríguez-Yáñez M, et al. Association between neuroserpin and molecular markers of brain damage in patients with acute ischemic stroke. J Transl Med 2011: 9: 58.
112. Domac FM, Somay G, Misirli H, Erenoglu NY. Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke. Neurosciences (Riyadh) 2007; 12: 25-30.
113. Zierath D, Tanzi P, Cain K, Shibata D, Becker K. Plasma α-melanocyte stimulating hormone predicts outcome in ischemic stroke. Stroke 2011; 42: 3415-3420.
114. Chakraborty B, Chowdhury D, Vishnoi G, Goswami B, Kishore J, Agarwal S. Interleukin-6 gene − 174 G/C promoter polymorphism predicts severity and outcome in acute ischemic stroke patients from north India. J Stroke Cerebrovasc Dis 2013: 22; 683-689.
115. Zeng L, Liu J, Wang Y, et al. Cocktail blood biomarkers: prediction of clinical outcomes in patients with acute ischemic stroke. Eur Neurol 2013: 69; 68-75.
116. Park SY, Kim J, Kim OJ, et al. Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: multiple blood markers profiling study. Crit Care 2013: 17; R45.
117. Sotgiu S, Zanda B, Marchetti B, et al. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur J Neurol 2006; 13: 505-513.
118. Chamorro A, Amaro S, Vargas M, et al. Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J Neurol Neurosurg Psychiatry 2006; 77: 1279-1281.
119. Serena J, Blanco M, Castellanos M, et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005; 36: 1921-1926.
120. Vila N, Filella X, Deulofeu R, Ascaso C, Abellana R, Chamorro A. Cytokine-induced inflammation and long-term stroke functional outcome. J Neurol Sci 1999; 162: 185-188.
121. Anuk T, Assayag EB, Rotstein R, et al. Prognostic implications of admission inflammatory profile in acute ischemic neurological events. Acta Neurol Scand 2002; 106: 196-199.
122. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002; 33: 2459-2464.
123. Christensen H, Boysen G. C-reactive protein and white blood cell count increases in the first 24 hours after acute stroke. Cerebrovasc Dis 2004; 18: 214-219.
124. Hamidon BB, Sapiah S, Nawawi H, Raymond AA. The prognostic value of C-reactive protein (CRP) levels in patients with acute ischaemic stroke. Med J Malaysia 2004; 59: 631-637.
125. Efstathiou SP, Tsiakou AG, Tsioulos DI, et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta 2007; 378: 78-85.
126. Vibo R, Kõrv J, Roose M, et al. Acute phase proteins and oxidised low-density lipoprotein in association with ischemic stroke subtype, severity and outcome. Free Radic Res 2007;41:282-287.
127. Geiger S, Holdenrieder S, Stieber P, et al. Nucleosomes as a new prognostic marker in early cerebral stroke. J Neurol 2007; 254: 617-623.
128. Topakian R, Strasak AM, Nussbaumer K, Haring HP, Aichner FT. Prognostic value of admission C-reactive protein in stroke patients undergoing IV thrombolysis. J Neurol 2008; 255: 1190-1196.
129. Ryu SR, Choi IS, Bian RX, Kim JH, Han JY, Lee SG. The effect of C-reactive protein on functional outcome in ischemic stroke patients. Int J Neurosci 2009; 119: 336-344.
130. Sienkiewicz-Jarosz H, Gałecka-Wolska M, Bidziński A, et al. Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients. Neurol Neurochir Pol 2009; 43: 126-133.
131. Song IU, Kim JS, Kim YI, Lee KS, Jeong DS, Chung SW. Relationship between high-sensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population. Cerebrovasc Dis 2009; 28: 545-550.
132. Varoglu AO, Kuyucu M, Demir R, Acemoglu H, Can I, Akcay F. Prognostic values of lesion volume and biochemical markers in ischemic and hemorrhagic stroke: a stereological and clinical study. Int J Neurosci 2009; 119: 2206-2218.
133. Brouns R, Verkerk R, Aerts T, et al. The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke. Neurochem Res 2010; 35: 1315-1322.
134. Song IU, Kim YD, Kim JS, Lee KS, Chung SW. Can high-sensitivity C-reactive protein and plasma homocysteine levels independently predict the prognosis of patients with functional disability after first-ever ischemic stroke? Eur Neurol 2010; 64: 304-310.
135. Rajeshwar K, Kaul S, Al-Hazzani A, et al. C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: correlation with clinical outcome. Inflammation 2012; 35: 978-984.
136. Tsai NW, Lee LH, Huang CR, et al. The association of statin therapy and high-sensitivity C-reactive protein level for predicting clinical outcome in acute non-cardioembolic ischemic stroke. Clin Chim Acta 2012; 413: 1861-1865.
137. Lai PT, Chen SY, Lee YS, Ho YP, Chiang YY, Hsu HY. Relationship between acute stroke outcome, aspirin resistance, and humoral factors. J Chin Med Assoc 2012; 75: 513-518.
138. Park HY, Jun CD, Jeon SJ, et al. Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS One 2012; 7: e51722.
139. Gensicke H, Seiffge DJ, Polasek AE, et al. Long-term outcome in stroke patients treated with IV thrombolysis. Neurology 2013; 80: 919-925.
140. Tiainen M, Meretoja A, Strbian D, et al. Body temperature, blood infection parameters, and outcome of thrombolysis-treated ischemic stroke patients. Int J Stroke 2013; 8: 632-638.
141. Zhang JL, Yin CH, Zhang Y, Zhao LB, Fu HJ, Feng JC. Plasma copeptin and long-term outcomes in acute ischemic stroke. Acta Neurol Scand 2013; 128: 372-380.
142. Tu WJ, Dong X, Zhao SJ, Yang DG, Chen H. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. J Neuroendocrinol 2013; 25: 771-778.
143. Abubakar SA, Okubadejo NU, Ojo OO, Oladipo O, Ojini FI, Danesi MA. Relationship between admission serum C-reactive protein and short term outcome following acute ischaemic stroke at a tertiary health institution in Nigeria. Niger J Clin Pract 2013; 16: 320-324.
144. Tu WJ, Zhao SJ, Liu TG, Yang DG, Chen H. Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke. Neurol Res 2013; 35: 912-921.
145. Kim SH, Lee JY, Kim do H, et al. Factors related to the initial stroke severity of posterior circulation ischemic stroke. Cerebrovasc Dis 2013; 36: 62-68.
146. Gong X, Zou X, Liu L, et al. Prognostic value of inflammatory mediators in 1-year outcome of acute ischemic stroke with middle cerebral artery stenosis. Mediators Inflamm 2013; 2013: 850714.
147. Men X, Li J, Zhang B, Zhang L, Li H, Lu Z. Homocysteine and C-reactive protein associated with progression and prognosis of intracranial branch atheromatous disease. PLoS One 2013; 8: e73030.
148. Ozkan AK, Yemisci OU, Saracgil Cosar SN, Oztop P, Turhan N. Can high-sensitivity C-reactive protein and ferritin predict functional outcome in acute ischemic stroke? A prospective study. Top Stroke Rehabil 2013; 20: 528-536.
149. Taheraghdam A, Aminnejad S, Pashapour A, Rikhtegar R, Ghabili K. Is there a correlation between hs-CRP levels and functional outcome of ischemic stroke? Pak J Med Sci 2013; 29: 166-169.
150. Karlinski M, Bembenek J, Grabska K, et al. Routine serum C-reactive protein and stroke outcome after intravenous thrombolysis. Acta Neurol Scand 2014; 130: 305-311.
151. Potpara TS, Polovina MM, Djikic D, Marinkovic JM, Kocev N, Lip GY. The association of CHA2DS2-VASc score and blood biomarkers with ischemic stroke outcomes: the Belgrade stroke study. PLoS One 2014; 9: e106439.
152. Deng WJ, Shen RL, Li M, Teng JF. Relationship between procalcitonin serum levels and functional outcome in stroke patients. Cell Mol Neurobiol 2015; 35: 355-361.
153. Sezer S, Uçar F, Ulusoy EK, et al. Serum amyloid A, fetuin-A, and pentraxin-3 levels in patients with ischemic stroke: novel prognostic biomarkers? Turk J Med Sci 2014; 44: 16-23.
154. Wang C, Gao L, Zhang ZG, et al. Procalcitonin is a stronger predictor of long-term functional outcome and mortality than high-sensitivity C-reactive protein in patients with ischemic stroke. Mol Neurobiol 2016; 53: 1509-1517.
155. Richard S, Lagerstedt L, Burkhard PR, Debouverie M, Turck N, Sanchez JC. E-selectin and vascular cell adhesion molecule-1 as biomarkers of 3-month outcome in cerebrovascular diseases. J Inflamm 2015; 12: 61.